Biological Predictive Factors of Response to ESA in Low Risk MDS Patients
NCT03598582
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Epoetin Zeta
Sponsor
Association pour la recherche sur les Affections Malignes en Immunologie Sanguine